Drug intelligence / Profile preview

QGCPU-03

Development stage: Preclinical
Lead developer: AceMapAI Biotechnology
Modality: Small Molecules

Overview

QGCPU-03 is a potential first-in-class small molecule therapeutic being developed by AceMapAI Biotechnology (also known as QureGenAI) for the treatment of anemia and chronic kidney disease (CKD). The drug was discovered and optimized using the company's proprietary Quantum AIDD (Artificial Intelligence Drug Discovery) platform. Currently, QGCPU-03 is at the preclinical candidate (PCC) stage, designated as PCC Ready. While the specific molecular target and mechanism of action have not been publicly disclosed, the compound is positioned as a novel approach to managing anemia associated with renal impairment.

Beyond the preview

Go deeper on QGCPU-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QGCPU-03.

Explore the full profile